NDAORALTABLET, EXTENDED RELEASEPriority Review
Approved
Jul 2020
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 6h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RUKOBIA (fostemsavir tromethamine) is an oral, extended-release small molecule approved by the FDA in July 2020 for treatment-experienced HIV patients with drug-resistant virus. It is an attachment inhibitor that blocks HIV entry into CD4+ T cells by targeting the gp120 envelope protein.
$91MPart D
LOE Approaching2.7 years to LOELimited market penetration with ~10K annual Part D claims signals niche positioning; smaller commercial team required vs. blockbuster antiretrovirals.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Worked on RUKOBIA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.